#50 Building AGI to solve aging - Kennedy Schaal & Rejuve.bio - SingularityNet - AI for drug and target discovery

Kennedy Schaal is the CEO of Rejuve.bio, a biotech company with the goal of solving aging by building AGI for drug discovery. Summary In this episode, Kennedy Schaal introduces her company Rejuve.bio which comes out of the SingularityNet. Kennedy Schaal and I discuss the intersection of data, AI, and collaboration in the longevity sector. We explore the importance of community engagement, the potential for shared data to advance research, and the role of marketing in promoting longevity initiatives. Kennedy emphasizes the need for a collective approach to solving aging-related issues and shares her personal commitment to community service and the arts. Links - ⁠⁠⁠⁠⁠⁠⁠Zelar City Website⁠⁠⁠⁠⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠What is Zelar City?⁠⁠⁠ - ⁠Rejuve.bio - ⁠This episode on YouTube Chapters 00:00 Intro to Rejuve.bio, Kennedy Schaal, and SingularityNet 00:38 The Methuselah Fruit Fly experiment 01:05 Why Kennedy Schaal is working in Longevity 05:38 Why Kennedy Schaal is working with SingularityNet 09:40 What is the scope of Rejuve Biotech? 10:44 Licensing model of the target discovery platform by Rejuve.bio 13:14 How does Rejuve.bio fit in SingularityNets vision of descentralization? (Rejuve.ai) 18:40 How are Rejuve.bio and Rejuve.ai connected? 20:05 How is it like to build a Biotech company 23:27 Kennedys experience with remote work in a biotech company 24:52 The hardest part of developing Rejuve.bio 27:22 The role of DeSci for solving aging 32:01 The role of Pop-up cities like Zelar for advancing longevity research 34:04 Kennedys advice to people starting out in longevity 36:56 Kennedy Schaals biggest learning from having a longevity company 38:28 What does Kennedy Schaal do in her free-time 41:29 How long do you want to live? @ Kennedy Schaal 43:28 Next interview and Links